Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity
Authors
Keywords
-
Journal
Immunotherapy
Volume 10, Issue 9, Pages 797-805
Publisher
Future Medicine Ltd
Online
2018-07-16
DOI
10.2217/imt-2017-0187
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy
- (2017) Annie N. M. Wong et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC
- (2017) Kyoichi Kaira et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments
- (2017) Katja Pinker et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors
- (2017) Sabrina Rossi et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data
- (2017) Pedro N Aguiar et al. Immunotherapy
- Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18 F-FDG PET/CT Imaging in Patients with Advanced Melanoma
- (2017) Steve Y. Cho et al. JOURNAL OF NUCLEAR MEDICINE
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model
- (2017) Arutselvan Natarajan et al. MOLECULAR IMAGING AND BIOLOGY
- Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
- (2017) Jung Han Kim et al. Oncotarget
- Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18 F-fluorodeoxyglucose positron emission tomography/computed tomography
- (2017) Kazuki Takada et al. Cancer Medicine
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery
- (2016) Egesta Lopci et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical Pharmacokinetics and Biodistribution Studies of 89 Zr-Labeled Pembrolizumab
- (2016) Christopher G. England et al. JOURNAL OF NUCLEAR MEDICINE
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
- (2016) Mitsunori Higuchi et al. World Journal of Surgical Oncology
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
- (2016) Chiara Nicolazzo et al. Scientific Reports
- Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes
- (2015) Arutselvan Natarajan et al. BIOCONJUGATE CHEMISTRY
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
- (2015) Antonio Calles et al. Journal of Thoracic Oncology
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
- (2015) M B Schabath et al. ONCOGENE
- Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
- (2015) Roy L. Maute et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started